Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACM Research Inc (ACMR) vs TransMedics Group Inc (TMDX) Price & Performance

ACM Research IncTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

ACM Research Inc vs TransMedics Group Inc — how do they compare? ACM Research Inc trades at $81.07 (market cap $5.57B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: ACM Research Inc is the larger of the two by market cap, and ACM Research Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

ACMRTMDX
Market Cap
$5.57B$3.10B
Sector
TechnologyTechnology
52-Week High
$126.89$150.42
52-Week Low
$24.93$61.99
Enterprise Value
$4.48B$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACM Research Inc

ACMR trades at $81.26, up 2.33% today, with a neutral technical signal and bearish moving averages. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $0.61 versus $0.42 expected, revenue growth of 36% year-over-year to $292.9 million, and raised 2026 guidance. Net income margin improved to 14.48% in 2026 from 10.43% in 2025, supported by robust orders and product expansion.

Outlook remains positive with an 80% analyst buy rating and consensus price target of $127.50, implying significant upside. Risks include high P/E of 37.7, negative operating cash flow, and semiconductor cycle volatility. Growth catalysts are new wet processing platforms and overseas expansion, but execution on guidance is critical.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.

Returns comparison

Trailing returns across standard periods

About ACM Research Inc

ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.

Read more on ACMR

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX